Skip to main content

White paper

Addressing extreme cost and lack of catheter lock options in the U.S.

The high cost of ethanol lock therapy has significant impact on patients.

December 5, 2024 | 1-minute read

The FDA’s unapproved drug initiative has had an impact on catheter lock therapy for home infusion patients. Patients who require a central venous access device (CVAD) are at a significant risk for catheter-associated bloodstream infections. The lack of options and high cost have created an urgent need in the U.S. for FDA-approved central line catheter lock solutions.

In this white paper learn about:

  • Challenges and costs of Ethanol Lock Therapy (ELT)
  • Need for FDA-approved alternative lock solutions

Download white paper

Related healthcare insights

View all pharmacy care insights
Subscribe to Pharmacy Provider Pulse Quarterly Newsletter

Subscribe to Optum Pharmacy Provider Pulse Quarterly Newsletter

Stay up to date on our Specialty and Infusion Pharmacy offerings and get important industry developments delivered directly to your inbox.

Celebrating the Unique Role of Optum Infusion Pharmacy Nurses

Article

Celebrating the unique role of Optum Infusion Pharmacy nurses

On average, Optum Infusion nurses spend approximately 1,300 hours per year providing care to patients. Hilary, an Optum Infusion nurse, knows this firsthand.

Infusion Nurse Kayaks Through Hurricane Damage to Give Care

Article

Infusion nurse kayaks through hurricane damage to administer care

An Optum Infusion Pharmacy nurse’s commitment to ensure her patients received their medication after a hurricane is just one example of the care team’s compassion and commitment.